Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Eltanexor works by trapping "tumor suppressing proteins" within the cell, thus causing the cancer cells to die or stop growing. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2,

Trial Details

NCT ID
NCT06399640
Phase
PHASE1
Sponsor
Vanderbilt-Ingram Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Eltanexor
  • Venetoclax
  • Bone Marrow Aspiration and Biopsy
  • Biospecimen Collection
Locations (sample)
  • Memphis, Tennessee, United States|35.14953,-90.04898
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • \- Age \>/= 18 years at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF; and must be able to meet all study requi…
  • For Myelodysplastic Syndrome (MDS):
  • Morphologically confirmed diagnosis of MDS with increased blasts (\>/= 5%), with a prior DNA methyltransferase inhibitor (DNMTi) treatment and prog…
  • For Acute Myeloid Leukemia (AML):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →